Horizon Discovery 'sorry' to see departure of experienced director Jonathan Milner
Gene editing and gene modulation technology firm Horizon Discovery Group announced on Thursday that non-executive director Jonathan Milner is stepping down from his role with immediate effect.
Milner, who held the role on Horizon’s board for 10 years, is the co-founder and deputy chairman of Abcam plc and has provided investment or support to over 40 companies throughout his career, most of them UK-based life science and high-tech start-ups.
Jonathan Milner said: "From my initial meeting with the founders through to the IPO, and becoming a world leader in gene editing, I feel enormously privileged to have been a part of this exciting journey. I continue to be encouraged and enthusiastic about the growth prospects of Horizon's business, and intend to remain a shareholder for the foreseeable future."
Milner is leaving the company to focus on other projects and is currently non-executive director at Repositive, HealX and Syndicate Room, and chairman of Axol Bioscience, Cambridge Allergy Therapy, and PhoreMost.
Ian Gilham, executive chairman of Horizon Discovery, said: “We are sorry to see Jonathan depart, but completely understand his decision to prioritise other commitments. We are extremely grateful for his valuable insights as a member of Horizon's board over many years and wish him well in his future, not least as a considerable founding shareholder of the Horizon business.”
As of 1149 BST, Horizon Discovery Group’s shares were down 2.41% at 182.50p.